Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Director departure
CC transcript
|
|
CALLISTO PHARMACEUTICALS INC (CLSP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/29/2013 |
SC 13D/A
| Hunter Robert Merrill reports a 0% stake in Callisto Pharmaceuticals, Inc. |
| 01/22/2013 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 01/22/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/22/2013 |
4
| Denoyer Bernard (Senior Vice President, Finance) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC|
Txns:
| Disposed/sold 100,000 options
@ $3.6, valued at
$360k
Disposed/sold 75,000 options
@ $1.38, valued at
$103.5k
Disposed/sold 75,000 options
@ $0.66, valued at
$49.5k
Disposed/sold 75,000 options
@ $0.26, valued at
$19.5k
|
|
| 01/22/2013 |
4
| Johnson Randall (Director) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC|
Txns:
| Disposed/sold 113,636 shares
@ $0
Disposed/sold 10,000 options
@ $1.8, valued at
$18k
Disposed/sold 75,000 options
@ $1.5, valued at
$112.5k
Disposed/sold 6,000 options
@ $1.17, valued at
$7k
Disposed/sold 3,000 options
@ $1.45, valued at
$4.4k
Disposed/sold 6,000 options
@ $0.77, valued at
$4.6k
Disposed/sold 3,000 options
@ $0.83, valued at
$2.5k
Disposed/sold 6,000 options
@ $0.47, valued at
$2.8k
Disposed/sold 6,500 options
@ $0.47, valued at
$3.1k
Disposed/sold 6,000 options
@ $0.08, valued at
$480
Disposed/sold 6,500 options
@ $0.08, valued at
$520 |
|
| 01/22/2013 |
4
| BRANCACCIO JOHN P (Director) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC|
Txns:
| Disposed/sold 113,636 shares
@ $0
Disposed/sold 75,000 options
@ $3.2, valued at
$240k
Disposed/sold 17,123 options
@ $1, valued at
$17.1k
Disposed/sold 6,000 options
@ $1.17, valued at
$7k
Disposed/sold 8,000 options
@ $1.45, valued at
$11.6k
Disposed/sold 6,000 options
@ $0.77, valued at
$4.6k
Disposed/sold 8,000 options
@ $0.83, valued at
$6.6k
Disposed/sold 6,000 options
@ $0.47, valued at
$2.8k
Disposed/sold 8,000 options
@ $0.47, valued at
$3.8k
Disposed/sold 6,000 options
@ $0.08, valued at
$480
Disposed/sold 8,000 options
@ $0.08, valued at
$640 |
|
| 01/22/2013 |
4
| JACOB GARY S (CEO) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC|
Txns:
| Disposed/sold 147,245 shares
@ $0
Disposed/sold 500,000 options
@ $1.5, valued at
$750k
Disposed/sold 275,000 options
@ $3, valued at
$825k
Disposed/sold 350,000 options
@ $1.01, valued at
$353.5k
Disposed/sold 150,000 options
@ $1.64, valued at
$246k
Disposed/sold 225,000 options
@ $0.81, valued at
$182.3k
Disposed/sold 390,000 options
@ $0.26, valued at
$101.4k
|
|
| 01/22/2013 |
4
| CERRONE GABRIEL (Director) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC|
Txns:
| Disposed/sold 2,184,672 shares
@ $0
Disposed/sold 261,000 options
@ $1.3, valued at
$339.3k
Disposed/sold 72,055 options
@ $1.3, valued at
$93.7k
Disposed/sold 75,000 options
@ $1.5, valued at
$112.5k
Disposed/sold 100,000 options
@ $3.2, valued at
$320k
Disposed/sold 375,000 options
@ $1.7, valued at
$637.5k
Disposed/sold 225,000 options
@ $0.96, valued at
$216k
Disposed/sold 390,000 options
@ $0.26, valued at
$101.4k
|
|
| 01/15/2013 |
8-K
| Quarterly results |
| 01/03/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/03/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/03/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 12/07/2012 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 11/19/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/14/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 10/16/2012 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 10/16/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/28/2012 |
10-Q/A
| Quarterly Report for the period ended June 30, 2012 [amend] |
| 08/20/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/14/2012 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 07/23/2012 |
8-K
| Form 8-K - Current report |
| 07/23/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 05/15/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 03/30/2012 |
10-K
| Annual Report for the period ended December 31, 2011 |
| 03/28/2012 |
SC 13D/A
| Hunter Robert Merrill reports a 16.1% stake in Callisto Pharmaceuticals, Inc. |
| 03/28/2012 |
4
| Hunter Robert Merrill (10% Owner) has filed a Form 4 on CALLISTO PHARMACEUTICALS INC |
| 11/14/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 08/15/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 08/03/2011 |
3
| CALLISTO PHARMACEUTICALS INC (10% Owner) has filed a Form 3 on SYNERGY PHARMACEUTICALS, INC. |
| 08/03/2011 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/03/2011 |
BW
| Synergy Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference |
| 05/18/2011 |
BW
| Synergy Pharmaceuticals Advances Its Preclinical Research Program For The Use Of Guanylate Cyclase C Agonists To Lower Cholesterol |
| 05/16/2011 |
10-Q
| Quarterly Report for the period ended March 31, 2011 |
| 05/03/2011 |
BW
| Synergy Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference |
|
|
|